Home > Insider Trading > Filing (0001181431-13-011493)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1365216	Sucampo Pharmaceuticals Inc.	SCMP	Pharmaceutical Preparations (2834)	133929237

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1384370	Ryuji Ueno	4520 East-West Highway Suite 300 Bethesda MD 20814	Ceo, Chief Scientific Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Disposition	2012-11-02	867	$5.00	25,545,501	No	4	S	Indirect	By S&R Technology Holdings, LLC
Class A Common Stock	Disposition	2013-01-08	29,307	$5.00	25,516,194	No	4	S	Indirect	By S&R Technology Holdings, LLC
Class A Common Stock	Disposition	2013-02-19	38,462	$5.14	25,477,732	No	4	S	Indirect	By S&R Technology Holdings, LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By S&R Technology Holdings, LLC
No	4	S	Indirect	By S&R Technology Holdings, LLC
No	4	S	Indirect	By S&R Technology Holdings, LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	148,530	Direct
Class A Common Stock	60,357	Indirect	By Wife

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by S&R Technology Holdings, LLC on August 29, 2012.
S&R Technology Holdings, LLC is wholly owned by Dr. Ueno and his wife. Dr. Ueno disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The prices reported are weighted average prices. The shares sold on January 8, 2013 were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The shares sold on February 19, 2013 were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Dr. Ueno disclaims beneficial ownership of the reported securities.